Sera from 98 primiparous Rh(D)-negative women were tested for leucocyte isoimmunization from blood samples taken at delivery and 3 months after, when prevention of Rh immunization was first checked. Lymphocytotoxic antibodies were demonstrated already at delivery in 16 cases (16.3%). Ten of the remaining 82 women whose serum was negative at delivery developed antibodies in the meantime, according to the tests carried out with serum samples taken 3 months after (12.2%). All batches of anti-D IgG used during the investigation period contained lymphocytotoxic antibodies. However, a protective effect against leucocyte isoimmunization is unlikely in these cases. More than half of the immunized women were already primed by the time of delivery, and a considerable percentage (12.2) of the rest became immunized afterwards. The incidence of immunization detected either at delivery or 3 months after,altogether 26.5%, moderately exceeds the figure for the indidence of lymphocytotoxic antibodies during second pregnancy in the authors’ own statistics, obtained with the same serological method (21.6%). In 46 cases at and after second delivery a similar relation was found with antibody incidence during third pregnancy.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.